EUCTR2013-004384-31-DE进行中（未招募）1 期
A Multicentre, Long-term Safety, Efficacy and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged =6 to <18 years with Functional Constipation
Sucampo AG0 个研究点目标入组 300 人开始时间: 2014年2月28日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent obtained from subject and/or parent/legal guardian (and assent from subject where applicable).
- •2.Subject must have completed the entire 12-week treatment period from the preceding study (SAG/0211PFC-1131) prior to enrolment.
- •3.Subject must continue to abstain from taking concomitant medication (prescribed or over-the-counter) that affects gastrointestinal motility; these medications include:
- •a.Cholinesterase inhibitors; anti-spasmodic, anti-diarrheal, anti-constipation, or prokinetic agents; laxative agents (e.g., PEG 3350), including homeopathic remedies;
- •b.Tricyclic antidepressants; or
- •c.Any medication, at the discretion of the Investigator, known to cause constipation or constipation-related symptoms.
- •Exceptions: Treatment with anticholinergic agents, SSRIs, SNRIs, or MAO inhibitors is allowed if a stable dose has been used for at least 30 days prior to the Baseline Visit (of the preceding study SAG/0211PFC-1131) and not likely to change during the study.
- •4.Subject (and if necessary, parent/legal guardian) must be willing and able to use or administer recommended (rectal and/or oral) rescue medications if needed.
- •5.If subject is taking a fibre supplement (e.g., Metamucil®, PerDiem®, Fybogel), usage must have been at a stable dose not likely to change during the study.
- •6.Subject and his/her parent/legal guardian must be willing and able to fill out his/her own diary
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 300
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Subject has current evidence of untreated faecal impaction.
- •2.Subject has experienced an adverse event during the SAG/0211PFC-1131 study which the Investigator considers to be clinically significant and would limit the subject’s ability to participate in the trial.
- •3.Subject has had a significant change in their medical status, newly diagnosed and uncontrolled cardiovascular, liver or lung disease, neurologic or psychiatric disorder, or other systemic disease, which the Investigator considers to be clinically significant and would limit the subject’s ability to participate in the trial.
- •4.Subject has developed abnormal laboratory test (haematology, urinalysis, or blood chemistry), which in the Investigator’s opinion is clinically significant, unexplained, and would limit the subject’s ability to participate in the trial.
- •5.Subject (female of childbearing potential) has a positive pregnancy test or refuses/is unwilling to undergo pregnancy testing, and/ does not agree to use protocol-specified contraceptive measures for the duration of the study.
- •6.Subject demonstrated non-compliance with study protocol (i.e., dosing schedule, visit schedule, diary completion, or study procedures) during the SAG/0211PFC-1131 study
研究者
相似试验
进行中（未招募）
1 期
ong-term safety extension study of lubiprostone for the treatment of paediatric functional constipation in subjects aged =6 to <18 yearsfunctional constipation in paediatric patientsMedDRA version: 18.0Level: PTClassification code 10010774Term: ConstipationSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-004384-31-FRSucampo AG300
进行中（未招募）
1 期
ong-term safety extension study of lubiprostone for the treatment of paediatric functional constipation in subjects aged =6 to <18 yearsEUCTR2013-004384-31-PLSucampo Pharma Americas, LLC415
进行中（未招募）
1 期
ong-term safety extension study of lubiprostone for the treatment of paediatric functional constipation in subjects aged =6 to <18 yearsEUCTR2013-004384-31-BESucampo AG418
进行中（未招募）
1 期
ong-term safety extension study of lubiprostone for the treatment of paediatric functional constipation in subjects aged =6 to <18 yearsEUCTR2013-004384-31-GBSucampo Pharma Americas LLC418
进行中（未招募）
1 期
ong-term safety extension study of lubiprostone for the treatment of paediatric functional constipation in subjects aged =6 to <18 yearsfunctional constipation in paediatric patientsMedDRA version: 17.1Level: PTClassification code 10010774Term: ConstipationSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-004384-31-NLSucampo AG300